Considering innate CD8 T-cells, further investigations are needed to determine whether their possible contributory role in cancer surveillance in CML could be extended to other cancers, and also whether their targeting by immune cheek-point inhibitors could enhance their anti-tumoral functions. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.